(VIANEWS) – SMARTCRAFT (SMCRT.OL), NAVAMEDIC (NAVA.OL), BAKKAFROST (BAKKA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SMARTCRAFT (SMCRT.OL)
18.1% sales growth and 11.51% return on equity
SmartCraft ASA provides software solutions to the construction industry in Norway, Sweden, and Finland. The company offers Cordel; Bygglet, a SaaS born in the cloud solution; EL-VIS, a solution for electricians; and Congrid, a cloud-based tool for project management in construction companies. It also provides HomeRun, a digital tool for construction, project communication, document, and procurement management; Kvalitetskontroll, a cloud-based project management solution and quality assurance platform for construction companies; El-verdi, a digital sales tool for electricians; and ELinn, a cloud based solution for electricians to handle project management services. The company was founded in 1987 and is headquartered in Hønefoss, Norway.
Earnings Per Share
As for profitability, SMARTCRAFT has a trailing twelve months EPS of kr0.54.
PE Ratio
SMARTCRAFT has a trailing twelve months price to earnings ratio of 38.89. Meaning, the purchaser of the share is investing kr38.89 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.51%.
Yearly Top and Bottom Value
SMARTCRAFT’s stock is valued at kr21.00 at 12:20 EST, way below its 52-week high of kr24.10 and way above its 52-week low of kr13.04.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 66.7% and 185.7%, respectively.
More news about SMARTCRAFT.
2. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 33.22. Meaning, the purchaser of the share is investing kr33.22 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
Volume
Today’s last reported volume for NAVAMEDIC is 11564 which is 70.92% below its average volume of 39778.
Moving Average
NAVAMEDIC’s worth is way above its 50-day moving average of kr35.37 and higher than its 200-day moving average of kr36.63.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 454.46M for the twelve trailing months.
More news about NAVAMEDIC.
3. BAKKAFROST (BAKKA.OL)
11.7% sales growth and 13.83% return on equity
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products under the Bakkafrost and Havsbrún brands in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through four segments: Farming FO; Farming SCT; Value Added Products; and Fishmeal, Oil and Fish Feed. The company is involved in the breeding and on-growing of salmon; harvesting, sale, and distribution of salmon; salmon farming, harvest, filleting, sales, and administration; and production of skinless and boneless portions of salmon. It also produces and sells fishmeal, fish oil, and fish feed. In addition, it engages in production of styrofoam boxes, and biogas and fertilizer; and operates trading of fishes, lumpfish farming business, and freight transportation of goods, as well as produce and sell canned fish products. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.
Earnings Per Share
As for profitability, BAKKAFROST has a trailing twelve months EPS of kr11.77.
PE Ratio
BAKKAFROST has a trailing twelve months price to earnings ratio of 45.11. Meaning, the purchaser of the share is investing kr45.11 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 8.9% and positive 68.9% for the next.
More news about BAKKAFROST.
4. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 5.32% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.31.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 75.48. Meaning, the purchaser of the share is investing kr75.48 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
Moving Average
VISTIN PHARMA’s value is above its 50-day moving average of kr22.73 and way above its 200-day moving average of kr19.49.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the current quarter and 6.6% for the next.
More news about VISTIN PHARMA.
5. DASSAULT SYSTEMES (DSY.PA)
5.5% sales growth and 14.06% return on equity
Dassault Systèmes SE provides software solutions and services worldwide. It offers SOLIDWORKS design software for mechanical and electronic printed circuit board design solutions, product data management, simulation, manufacturing, and technical communication; CATIA, an engineering and design software for product 3D computer-aided design; GEOVIA for intersection of natural resources, infrastructure and urban planning; and BIOVIA that develops chemicals, biologics, and materials experiences. The company provides SIMULIA that delivers realistic simulation applications; DELMIA, which enables global industrial operations; 3DVIA that provides 3D space planning solutions; and ENOVIA that enables to plan and track the definition of success for customer. In addition, it offers Centric PLM, a product lifecycle management software solution; 3DEXCITE, a real-time 3D visualization software; NETVIBES, which enables organizations to gather, align, and enrich big data; 3DEXPERIENCE platform that provides organizations a holistic and real-time view of their business activities and ecosystem, as well as connecting people, ideas, data, and solutions together in a single environment; and MEDIDATA, a clinical research study software that provides evidences and insights to pharmaceutical, biotech, medical device, and diagnostic companies, as well as academic researchers. It primarily serves companies in the transportation and mobility; industrial equipment; aerospace and defense; high-tech; life sciences and healthcare; energy and materials; home and lifestyle; construction, cities, and territories; consumer packaged goods and retail; marine and offshore; and business services. Dassault Systèmes SE was incorporated in 1981 and is headquartered in Vélizy-Villacoublay, France.
Earnings Per Share
As for profitability, DASSAULT SYSTEMES has a trailing twelve months EPS of €0.69.
PE Ratio
DASSAULT SYSTEMES has a trailing twelve months price to earnings ratio of 52.36. Meaning, the purchaser of the share is investing €52.36 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.06%.
Yearly Top and Bottom Value
DASSAULT SYSTEMES’s stock is valued at €36.13 at 12:20 EST, way below its 52-week high of €41.99 and way above its 52-week low of €32.23.
Moving Average
DASSAULT SYSTEMES’s worth is under its 50-day moving average of €36.20 and below its 200-day moving average of €37.27.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 3.8% and 8.8%, respectively.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 29, 2023, the estimated forward annual dividend rate is 0.21 and the estimated forward annual dividend yield is 0.58%.
More news about DASSAULT SYSTEMES.
